Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study

References

• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative Colitis. Part 1: definitions, Diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. Crohns Colitis. 2017;11:649–670.
   Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178
   PubMed Web of Science ®Google Scholar
• Ben-Horin S. Loss of response to anti-tumor necrosis factors: what is the next step? Dig Dis. 2014;32(4):384–388. doi: 10.1159/000358142
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135. doi: 10.1038/ctg.2015.63
   PubMed Web of Science ®Google Scholar
• Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–698. doi: 10.1038/ajg.2011.103
   PubMed Web of Science ®Google Scholar
• Tursi A, Mocci G, Lorenzetti R, et al. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol. 2021;33(5):670–679. doi: 10.1097/MEG.0000000000002087
   PubMed Web of Science ®Google Scholar
• Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–729. doi: 10.1038/nm.3895
   PubMed Web of Science ®Google Scholar
• Stelara ema.europa.eu. https://www.ema.europa.eu/en/medicines/human/EPAR/stelara%23
   Google Scholar
• Regime di rimborsabilità e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano “Stelara.”Gazzetta Ufficiale Della Repubblica Italiana del 03.12.2021; Serie generale – n. 288: p. 31–33
   Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. UNIFI Study Group. Ustekinumab as induction and maintenance therapy for Ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi: 10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Abreu MT, Rowbotham DS, Danese S, et al. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension. J Crohns Colitis. 2022;16(8):1222–1234. doi: 10.1093/ecco-jcc/jjac030
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Iborra M, et al. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15(11):1846–1851. doi: 10.1093/ecco-jcc/jjab070
   PubMed Web of Science ®Google Scholar
• Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021;54(7):944–951. doi: 10.1111/apt.16544
   PubMed Web of Science ®Google Scholar
• Amiot A, Filippi J, Abitbol V, et al. UC-USK-GETAID Study Group. Effectiveness and safety of ustekinumab induction therapy in 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. 2020;51(11):1039–1046.
   PubMed Web of Science ®Google Scholar
• Chiappetta MC, Viola A, Mastronardi M, et al. One-year effectiveness and safety of Ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021;21(11):1483–1489. doi: 10.1080/14712598.2021.1981855
   PubMed Web of Science ®Google Scholar
• Hong SJ, Cleveland NK, Akiyama S, et al. Real-world effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States. Crohn Colitis. 2021;360(3):1–8. doi: 10.1093/crocol/otab002
   Google Scholar
• Honap S, Al-Hillawi L, Baillie S, et al. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol. 2022;13(6):517–523. doi: 10.1136/flgastro-2022-102168
   PubMed Web of Science ®Google Scholar
• Satsangi J. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749–753. doi: 10.1136/gut.2005.082909
   PubMed Web of Science ®Google Scholar
• Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med. 1987;317(26):1625–1629. doi: 10.1056/NEJM198712243172603
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Kishi M, Hirai F, Takatsu N, et al. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol. 2022;57(4):246–266. doi: 10.1007/s00535-022-01862-y
   PubMed Web of Science ®Google Scholar
• Taxonera C, Olivares D, López-García ON, et al. Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–619. doi: 10.1111/apt.17386
   PubMed Web of Science ®Google Scholar
• Parakkal D, Johnson A, Fenster M, et al. Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a multi-centre study. J Crohn’s Colitis. 2021;15(Supplement_1):SS349–S350. doi: 10.1093/ecco-jcc/jjab076.449
   Google Scholar
• Tursi A, Mocci G, Cuomo A, et al. Real-life efficacy and safety of ustekinumab as second- or third-line therapy in Crohn’s disease: results from a large Italian cohort study. Eur Rev Med Pharmacol Sci. 2021;25(4):2099–2108. doi: 10.26355/eurrev_202102_25115
   PubMed Web of Science ®Google Scholar
• Papa A, Scaldaferri F, Covino M, et al. Impact of SARS-CoV-2 infection on the course of inflammatory Bowel disease in patients treated with biological therapeutic agents: a case-control study. Biomedicines. 2022;10(4):843. doi: 10.3390/biomedicines10040843
   PubMed Web of Science ®Google Scholar
• Papa A, Gasbarrini A, Tursi A. Epidemiology and the impact of therapies on the outcome of COVID-19 in patients with inflammatory bowel disease. Am J Gastroenterol. 2020;115(10):1722–1724. doi: 10.14309/ajg.0000000000000830
   PubMed Web of Science ®Google Scholar
• Iborra M, Ferreiro-Iglesias R, Martín-Arranz MD, et al. Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a Spanish open-label cohort. Scand J Gastroenterol. 2023 Nov 6:1–9. Online ahead of print. doi: 10.1080/00365521.2023.2278427
   Google Scholar